|
Patent landscape, scope, and claims: |
Summary of Patent US10,669,236
United States Patent 10,669,236, titled “Methods of treating cancer with bromodomain inhibitors,” was granted on June 2, 2020, to Hoffmann-La Roche Inc. The patent broadly covers novel bromodomain inhibitors and their use in treating various cancers, particularly hematological malignancies and solid tumors. It claims specific chemical entities, pharmaceutical compositions, and methods of treatment. This patent represents a strategic move in the oncology space, aiming to broaden Roche’s portfolio of epigenetic modulators.
Scope of Patent US10,669,236
What is the primary inventive concept?
The patent claims cover heterocyclic compounds, specifically bromodomain inhibitors that bind to bromodomain-containing proteins such as BRD4, BRD2, BRD3, and BRDT. These compounds modulate epigenetic regulation, thereby inhibiting cancer cell proliferation.
Key structural features covered by the claims
| Chemical Class |
Core Structure |
Substituents |
Notable Features |
| Heteroaryl compounds |
Heteroaryl rings fused with heterocycles |
Variable R-groups, halogens, alkyl groups |
Designed for high affinity and selectivity towards bromodomains |
| Benzodiazepine derivatives |
Bicyclic frameworks fused with heteroatoms |
Specific substitutions enhancing cell permeability |
Emphasized for improved pharmacokinetics |
| Linkers and substituents |
Alkyl, polyethylene glycol chains |
For solubility and bioavailability |
Specific linkage sites for conjugation |
Claims Overview
- Compound claims: 30+ claims covering individual compounds, including those with specific substituents such as trifluoromethyl, methyl, or methoxy groups on the heterocyclic core.
- Use claims: Methods for treating cancers—particularly lymphoma, leukemia, multiple myeloma, breast, and lung cancers—not limited to a specific disease.
- Method of administration: Claims include oral, intravenous, and topical routes.
- Combination therapies: Claims extend to administering the bromodomain inhibitor alongside other anticancer agents, such as chemotherapeutics or immune checkpoint inhibitors.
Claim types and their implications
| Claim Type |
Description |
Implication |
| Composition claims |
Cover specific chemical entities |
Protect the chemical space of bromodomain inhibitors |
| Method claims |
Use of compounds in cancer treatment |
Enforceability depends on specific treatment protocols |
| Combination claims |
Use of inhibitors with other drugs |
Broader scope for combination therapies |
| Formulation claims |
Specific formulations for delivery |
Protect proprietary pharmaceutical compositions |
Patent Landscape for Bromodomain Inhibitors in the U.S.
Major players
| Company |
Notable Patents/Applications |
Focus Area |
| Roche |
US10,669,236; others |
Broad spectrum bromodomain inhibitors |
| GSK |
Filed multiple applications targeting CBP/p300 |
Transcriptional and epigenetic modulation |
| Constellation Pharmaceuticals (Merck) |
Several targeting BRD4 |
Oncology and fibrosis |
| Accure Therapeutics |
Specific compounds for neurodegenerative diseases but overlapping spaces |
Bromodomain targeting |
Patent families and related filings
- The patent is part of a family with corresponding applications in Europe (EP), Japan (JP), and Chinese (CN).
- Related applications explore specific chemical sub-classes and expanded therapeutic indications.
Timeline of patent filings and grants
| Date |
Action |
Patent/Publication No. |
| November 20, 2018 |
Filing date of provisional application |
– |
| June 2, 2020 |
USPTO grant |
US10,669,236 |
| Subsequent filings |
Patent family extensions |
Pending or issued |
Legal status and exclusivity
- Post-grant term: Expected expiration around June 2038 (20-year patent term from filing, adjusted for patent term adjustments).
- Potential for challenge: As a composition of matter patent, it is susceptible to validity challenges based on novelty or obviousness, notably in the context of prior art.
Comparison with Related Bromodomain Patent Literature
| Patent/Application |
Focus |
Top Claims |
Notable Differences |
| US10,669,236 |
Specific heterocyclic bromodomain inhibitors |
Narrower chemical scope with particular substituents |
Emphasis on detailed structural features |
| EP3005670 |
Targeting p300/CBP bromodomains |
Focus on transcriptional regulators |
Broader chemical class with different target domains |
| WO2019045326 |
Dual bromodomain inhibitors for cancer |
Focus on dual inhibition to enhance efficacy |
Combines multiple bromodomains in one compound |
Strategic and Patentability Insights
| Aspect |
Analysis |
| Patent Novelty |
Specific heteroaryl structures with defined substituents but overlapping with known bromodomain inhibitors |
| Inventive Step |
Novel combinations and specific substitutions likely inventive over prior art |
| Freedom to Operate (FTO) |
Narrow claims focus on specific chemical entities reduce risk but conduct comprehensive FTO analysis |
| Geographic Coverage |
US patent grants patent rights in the U.S.; equivalent applications in key markets |
| Lifecycle Management |
Opportunities for filing divisional and continuation applications to expand scope |
Implications for Industry and Business
- Roche’s patent constrains competitors from using similar heteroaryl structures for bromodomain inhibition in cancer therapy within the US.
- The patent supports flexibility in combination therapies with existing drugs, potentially strengthening Roche’s market position.
- The broad claim scope allows for future patent applications covering alternative chemical modifications and new indications.
Conclusion and Key Takeaways
- Broad coverage of heterocyclic bromodomain inhibitors targeting oncogenic epigenetic pathways.
- Claims encompass both compounds and methods, enabling Roche to defend and expand its therapeutic portfolio.
- The patent landscape demonstrates active innovation with major players filing increasingly sophisticated bromodomain-related IP.
- Strategic considerations include detailed analysis of chemical space, potential overlaps with prior art, and scope for licensing or litigation opportunities.
FAQs
1. What types of cancer can be treated with the compounds claimed in US10,669,236?
The patent specifically mentions hematologic cancers such as lymphoma, leukemia, multiple myeloma, and solid tumors including breast and lung cancers.
2. How does this patent impact competitors developing bromodomain inhibitors?
It narrows their freedom to operate in the specific heteroaryl chemical space in the U.S., potentially requiring design-around strategies or licensing.
3. Can these compounds be combined with other therapies?
Yes, the patent explicitly claims methods that include combination therapy with chemotherapy, immunotherapy, and targeted agents.
4. Are there known prior art references that challenge the novelty of these compounds?
While similar inhibitors exist in the literature, the specific structural claims and substitutions in US10,669,236 are considered novel and non-obvious at the time of grant.
5. What is the expected duration of patent protection for these compounds?
Typically, until around June 2038, assuming no patent term adjustments or extensions.
References
[1] United States Patent US10,669,236. “Methods of treating cancer with bromodomain inhibitors.” June 2, 2020.
[2] Patent family documentation and published applications.
[3] Market reports on bromodomain inhibitors in oncology.
[4] Regulatory and legal analyses of epigenetic drugs IP landscape.
More… ↓
⤷ Start Trial
|
